Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer

Cancer

Volumn 116, Issue 5, 2010, Pages 1344-1349

  Ramalingam, Suresh S ^a   Foster, Judy ^b   Gooding, William ^a   Evans, Terry ^b   Sulecki, Matthew ^b   Belani, Chandra P ^a,c  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Efficacy; Irinotecan; Paclitaxel; Small cell lung cancer

Indexed keywords

ATROPINE; DEXAMETHASONE; DIPHENHYDRAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IRINOTECAN; PACLITAXEL;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; ATAXIA; BONE MARROW; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FLUSHING; GRANULOCYTE; HEARTBURN; HEMOPTYSIS; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTION; KIDNEY FUNCTION; LETHARGY; LEUKOCYTE COUNT; LIVER FUNCTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; NEUTROPHIL COUNT; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SWEATING; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RECURRENCE; RETREATMENT; SMALL CELL LUNG CARCINOMA;

EID: 77149149415     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24753     Document Type: Article

References (21)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24: 4539-4544.
2. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282-291.
3. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83:855-861.
4. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658-667.
5. Fukuoka M, Masuda N. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol. 1994;34(suppl):S105-S111.
6. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225-1229.
7. Fukuoka M, Masuda N, Kudoh S, Negoro S. Irinotecan in small-cell lung cancer - Japanese trials. Oncology (Williston Park). 2000;14:57-62.
8. Pei XH, Nakanishi Y, Takayama K, et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs. 1997;8:231-237.
9. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994;86:1517-1524.
10. Murren JR, Peccerillo K, DiStasio SA, et al. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemother Pharmacol. 2000;46:43-50.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
12. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441-5447.
13. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/ cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24:2044-2051.
14. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346: 85-91.
15. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038-2043.
16. Natale NB, Lara P, Chansky K, et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC) [abstract]. J Clin Oncol. 2008;26(suppl):400s. Abstract 7512.
17. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24:5448-5453.
18. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003;9:5880-5887.
19. Ramalingam S, Mack PC, Vokes E, et al. Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): a California Consortium phase II study (NCI # 7097) [abstract]. J Clin Oncol. 2008;26(suppl):443s. Abstract 8078.
20. Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008; 26:870-876.
21. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421-3428.